Fmr LLC Ocugen, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Ocugen, Inc. stock. As of the latest transaction made, Fmr LLC holds 126,229 shares of OCGN stock, worth $124,966. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126,229

Previous 122,099 3.38%

Holding current value

$124,966

Previous $200,000 2.5%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.18 - $1.98 $4,873 - $8,177	4,130 Added 3.38%	126,229 $195,000
Q1 2024 May 13, 2024	BUY	$0.5 - $1.83 $1,844 - $6,750	3,689 Added 3.12%	122,099 $200,000
Q4 2023 Feb 13, 2024	SELL	$0.36 - $0.57 $19,551 - $30,956	-54,310 Reduced 31.44%	118,410 $67,000
Q3 2023 Nov 13, 2023	BUY	$0.4 - $0.62 $59,896 - $92,840	149,742 Added 651.68%	172,720 $69,000
Q2 2023 Aug 11, 2023	BUY	$0.45 - $0.88 $4,768 - $9,324	10,596 Added 85.58%	22,978 $12,000
Q1 2023 May 11, 2023	BUY	$0.82 - $1.33 $7,834 - $12,706	9,554 Added 337.84%	12,382 $10,000
Q4 2022 Feb 13, 2023	SELL	$1.11 - $1.87 $490 - $826	-442 Reduced 13.52%	2,828 $3,000
Q3 2022 Nov 10, 2022	BUY	$1.75 - $3.1 $1,361 - $2,411	778 Added 31.22%	3,270 $6,000
Q2 2022 Aug 12, 2022	SELL	$1.83 - $3.45 $15,501 - $29,224	-8,471 Reduced 77.27%	2,492 $6,000
Q1 2022 May 13, 2022	BUY	$2.34 - $4.72 $24,946 - $50,319	10,661 Added 3530.13%	10,963 $36,000
Q4 2021 Feb 14, 2022	BUY	$4.38 - $15.67 $1,314 - $4,701	300 Added 15000.0%	302 $1,000
Q3 2021 Nov 15, 2021	SELL	$6.36 - $8.51 $76 - $102	-12 Reduced 85.71%	2 $0
Q2 2021 Aug 13, 2021	BUY	$5.52 - $15.68 $77 - $219	14 New	14 $0

Others Institutions Holding OCGN

# of Institutions

110

Shares Held

66.8M

Call Options Held

516K

Put Options Held

272K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $214M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account